Benitec Biopharma (NASDAQ:BNTC – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $4.55 million for the quarter. Investors may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Thursday, May 21, 2026 at 9:30 AM ET.
Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Benitec Biopharma Stock Down 1.6%
BNTC opened at $12.08 on Tuesday. The firm has a 50 day moving average price of $11.77 and a 200-day moving average price of $12.40. Benitec Biopharma has a twelve month low of $9.85 and a twelve month high of $17.15. The stock has a market capitalization of $414.95 million, a price-to-earnings ratio of -10.60 and a beta of 0.28.
Wall Street Analyst Weigh In
Read Our Latest Research Report on Benitec Biopharma
Institutional Trading of Benitec Biopharma
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its holdings in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 904 shares during the last quarter. Truvestments Capital LLC boosted its position in shares of Benitec Biopharma by 156.5% in the fourth quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,339 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Benitec Biopharma in the third quarter worth approximately $79,000. JPMorgan Chase & Co. bought a new position in shares of Benitec Biopharma in the second quarter worth approximately $80,000. Finally, Bank of America Corp DE boosted its position in shares of Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,587 shares during the period. 52.19% of the stock is owned by hedge funds and other institutional investors.
About Benitec Biopharma
Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Featured Stories
- Five stocks we like better than Benitec Biopharma
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
